Disparities in Survival Outcomes Between Locally Advanced Cervical Squamous Cell Carcinoma and Adenocarcinoma Treated with Chemoradiotherapy

References

• Singh D, Vignat J, Lorenzoni V, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023;11(2):e197–e206. doi:10.1016/S2214-109X(22)00501-0
   PubMed Web of Science ®Google Scholar
• Xia C, Dong X, Li H, et al. Cancer statistics in China and the United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(5):584–590. doi:10.1097/CM9.0000000000002108
   PubMed Web of Science ®Google Scholar
• Fujiwara K, Monk B, Devouassoux-Shisheboran M. Adenocarcinoma of the uterine cervix: why is it different? Curr Oncol Rep. 2014;16(12):416.
   PubMed Web of Science ®Google Scholar
• Gadducci A, Guerrieri ME, Cosio S. Adenocarcinoma of the uterine cervix: pathologic features, treatment options, clinical outcome and prognostic variables. Crit Rev Oncol Hematol. 2019;135:103–114. doi:10.1016/j.critrevonc.2019.01.006
   PubMed Web of Science ®Google Scholar
• Shoji T, Takatori E, Saito T, et al. Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix. Cancer Chemother Pharmacol. 2013;71(3):657–662. doi:10.1007/s00280-012-2052-2
   PubMed Web of Science ®Google Scholar
• Okada S, Tsuda H, Ohmi K, et al. Immature glandular features in squamous cell carcinoma of the uterine cervix as an independent indicator of resistance to radiotherapy. Int J Gynecol Cancer. 2002;12(3):277–285. doi:10.1136/ijgc-00009577-200205000-00007
   PubMed Web of Science ®Google Scholar
• Davy ML, Dodd TJ, Luke CG, Roder DM. Cervical cancer: effect of glandular cell type on prognosis, treatment, and survival. Obstet Gynecol. 2003;101(1):38–45. doi:10.1016/s0029-7844(02)02275-5
   PubMed Web of Science ®Google Scholar
• Shimada M, Nishimura R, Nogawa T, et al. Comparison of the outcome between cervical adenocarcinoma and squamous cell carcinoma patients with adjuvant radiotherapy following radical surgery: SGSG/TGCU Intergroup Surveillance. Mol Clin Oncol. 2013;1(4):780–784. doi:10.3892/mco.2013.112
   PubMedGoogle Scholar
• Yokoi E, Mabuchi S, Takahashi R, et al. Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma. J Gynecol Oncol. 2017;28(2):e19. doi:10.3802/jgo.2017.28.e19
   PubMed Web of Science ®Google Scholar
• Li J, Xue X, Zhang Y, et al. The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma - A multi-center study in Chinese patients with uterine cervical cancer. Gynecol Oncol. 2023;175:133–141. doi:10.1016/j.ygyno.2023.05.071
   PubMed Web of Science ®Google Scholar
• Nicolás-Párraga S, Alemany L, de Sanjosé S, Bosch FX, Bravo IG; RIS HPV TT and HPV VVAP study groups. Differential HPV16 variant distribution in squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma. Int J Cancer. 2017;140(9):2092–2100. doi:10.1002/ijc.30636
   PubMed Web of Science ®Google Scholar
• Stolnicu S, Hoang L, Soslow RA. Recent advances in invasive adenocarcinoma of the cervix. Virchows Arch. 2019;475(5):537–549. doi:10.1007/s00428-019-02601-0
   PubMed Web of Science ®Google Scholar
• Wright AA, Howitt BE, Myers AP, et al. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 2013;119(21):3776–3783. doi:10.1002/cncr.28288
   PubMed Web of Science ®Google Scholar
• de Juan A, Redondo A, Rubio MJ, et al. SEOM clinical guidelines for cervical cancer (2019). Clin Transl Oncol. 2020;22(2):270–278. doi:10.1007/s12094-019-02271-z
   PubMed Web of Science ®Google Scholar
• Fujiwara H, Yokota H, Monk B, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S96–S101. doi:10.1097/IGC.0000000000000263
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology. Cervical Cancer 2023. Version 1. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf. Accessed February 29, 2024.
   Google Scholar
• Zhou J, Wu SG, Sun JY, et al. Comparison of clinical outcomes of squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the uterine cervix after definitive radiotherapy: a population-based analysis. J Cancer Res Clin Oncol. 2017;143(1):115–122. doi:10.1007/s00432-016-2246-9
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER Research Plus Data, 18 Registries, Nov 2020 Sub (2000–2018) - Linked To County Attributes - Total U.S., 1969–2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021, based on the November 2020 submission. Available from: www.seer.cancer.gov. Accessed February 29, 2024.
   Google Scholar
• Hu K, Wang W, Liu X, Meng Q, Zhang F. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy. Radiat Oncol. 2018;13(1):249. doi:10.1186/s13014-018-1197-5
   PubMedGoogle Scholar
• Rose PG, Java JJ, Whitney CW, Stehman FB, Lanciano R, Thomas GM. Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation. Gynecol Oncol. 2014;135(2):208–212. doi:10.1016/j.ygyno.2014.08.018
   PubMed Web of Science ®Google Scholar
• Suh DH, Ha HI, Lee YJ, Lim J, Won YJ, Lim MC. Incidence and treatment outcomes of uterine cervical cancer in Korea 1999–2018 from the national cancer registry. J Gynecol Oncol. 2023;34(2):e39. doi:10.3802/jgo.2023.34.e39
   PubMed Web of Science ®Google Scholar
• Smith AJB, Beavis AL, Rositch AF, Levinson K. Disparities in diagnosis and treatment of cervical adenocarcinoma compared with squamous cell carcinoma: an analysis of the National Cancer Database, 2004–2017. J Low Genit Tract Dis. 2023;27(1):29–34. doi:10.1097/LGT.0000000000000702
   PubMed Web of Science ®Google Scholar
• Molijn A, Jenkins D, Chen W, et al. The complex relationship between human papillomavirus and cervical adenocarcinoma. Int J Cancer. 2016;138(2):409–416. doi:10.1002/ijc.29722
   PubMed Web of Science ®Google Scholar
• Jenkins D, Molijn A, Kazem S, et al. Molecular and pathological basis of HPV-negative cervical adenocarcinoma seen in a global study. Int J Cancer. 2020;147(9):2526–2536. doi:10.1002/ijc.33124
   PubMed Web of Science ®Google Scholar
• Chen W, Molijn A, Enqi W, et al. The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma: a hospital based nation-wide multi-center retrospective study across China. Int J Cancer. 2016;139(12):2687–2697. doi:10.1002/ijc.30401
   PubMed Web of Science ®Google Scholar
• Wu SG, Sun JY, He ZY, Chen QH, Zhou J. Early-stage node negative cervical adenocarcinoma and squamous cell carcinoma show similar survival outcomes after hysterectomy: a population-based study. J Gynecol Oncol. 2017;28(6):e81. doi:10.3802/jgo.2017.28.e81
   PubMed Web of Science ®Google Scholar
• Meng Y, Chu T, Lin S, et al. Clinicopathological characteristics and prognosis of cervical cancer with different histological types: a population-based cohort study. Gynecol Oncol. 2021;163(3):545–551. doi:10.1016/j.ygyno.2021.10.007
   PubMed Web of Science ®Google Scholar
• Stolnicu S, Barsan I, Hoang L, et al. International Endocervical Adenocarcinoma Criteria and Classification (IECC): a New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix. Am J Surg Pathol. 2018;42(2):214–226. doi:10.1097/PAS.0000000000000986
   PubMed Web of Science ®Google Scholar
• Hsieh HY, Lu CH, Wang L. Long-term treatment outcomes/toxicities of definite chemoradiotherapy (intensity-modulated radiation therapy) for early-stage ”bulky” cervical cancer and survival impact of histological subtype. J Formos Med Assoc. 2023;122(3):221–229. doi:10.1016/j.jfma.2022.10.012
   PubMed Web of Science ®Google Scholar
• Kang JH, Cho WK, Yeo HJ, et al. Prognostic significance of tumor regression rate during concurrent chemoradiotherapy in locally advanced cervix cancer: analysis by radiation phase and histologic type. J Clin Med. 2020;9(11):3471. doi:10.3390/jcm9113471
   PubMed Web of Science ®Google Scholar
• Arakaki Y, Ariga T, Heianna J, et al. Long-term outcomes of cervical adenocarcinoma treated with concurrent chemoradiotherapy using paclitaxel and cisplatin. In Vivo. 2020;34(5):2739–2743. doi:10.21873/invivo.12096
   PubMed Web of Science ®Google Scholar
• Xiong Y, Liu J, Chen S, et al. Combination of external beam radiotherapy and Californium (Cf)-252 neutron intracavity brachytherapy is more effective in control of cervical squamous cell carcinoma than that of cervical adenocarcinoma. Med Oncol. 2015;32(9):231. doi:10.1007/s12032-015-0670-3
   PubMed Web of Science ®Google Scholar